




RealRate

PHARMACEUTICAL 2020

Northwest Biotherapeutics INC
Rank 343 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 6.2% points. The greatest weakness of Northwest Biotherapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 191% points.

The company's Economic Capital Ratio, given in the ranking table, is 46%, being 192% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	3,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	41,194
Liabilities, Non-Current	11,502
Other Assets	5,648
Other Compr. Net Income	-164
Other Expenses	3,742
Other Liabilities	0
Other Net Income	7,167
Other Revenues	2,410
Property and Equipment	281
Research and Development	13,590
Selling, General and Administrative Expense	12,541

Output Variable	Value in 1000 USD
Assets	9,129
Liabilities	52,696
Expenses	29,873
Revenues	2,410
Stockholders Equity	-43,567
Net Income	-20,296
Comprehensive Net Income	-20,378
BaseVar	50,720
ECR before LimitedLiability	-373%
Economic Capital Ratio	46%